Choi Hye-Ryeon, Koo Ja-Seung, Lee Cho-Rok, Lee Jan-Dee, Kang Sang-Wook, Jo Young-Seok, Chung Woong-Youn
Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Korea.
Department of Pathology, Yonsei University College of Medicine, Seoul 03722, Korea.
Biology (Basel). 2021 Jul 17;10(7):677. doi: 10.3390/biology10070677.
The most common genetic backgrounds of hereditary paraganglioma and pheochromocytoma (PPGL) are germline mutations. Given the fact that the immunohistochemistry (IHC) result for SDHB is always negative regardless of the type of mutation, we aimed to evaluate the efficacy of using SDHB IHC for screening mutations in PPGL cases. In total, 52 patients who underwent surgery for PPGL treatment between 2006 and 2020 and underwent genetic analysis at diagnosis were included. Tissue microarrays (TMAs) were constructed with PPGL tissues and IHC for SDHB was performed on TMA sections. All 10 patients with SDHB-negative IHC contained or mutations. The genetic test results of patients with SDHB-weakly positive IHC varied (one , two , one , and three unknown gene mutations). There were no mutations in the SDHB-positive IHC group. Six patients with weakly positive SDHB IHC with primarily unknown genetic status were re-called and underwent next-generation sequencing. None of them had mutations. In conclusion, SDHB-negative IHC is a cost-effective and reliable method to predict mutations. However, in the case of weakly positive SDHB staining, an additional gene study should be considered.
遗传性副神经节瘤和嗜铬细胞瘤(PPGL)最常见的遗传背景是胚系突变。鉴于无论突变类型如何,SDHB的免疫组织化学(IHC)结果始终为阴性,我们旨在评估使用SDHB IHC筛查PPGL病例突变的有效性。总共纳入了2006年至2020年间因PPGL治疗接受手术且在诊断时进行了基因分析的52例患者。用PPGL组织构建组织微阵列(TMA),并在TMA切片上进行SDHB的IHC检测。所有10例SDHB IHC阴性的患者均存在 或 突变。SDHB IHC弱阳性患者的基因检测结果各不相同(1例 、2例 、1例 以及3例未知基因突变)。SDHB IHC阳性组未发现 突变。对6例SDHB IHC弱阳性且主要遗传状态未知的患者进行了再次召回并进行了二代测序。他们均未发现 突变。总之,SDHB阴性IHC是预测 突变的一种经济有效且可靠的方法。然而,在SDHB染色弱阳性的情况下,应考虑进行额外的基因研究。